Literature DB >> 23883191

Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Nikhil Neelkantan1, Alina Mikhaylova, Adam Michael Stewart, Raymond Arnold, Visar Gjeloshi, Divya Kondaveeti, Manoj K Poudel, Allan V Kalueff.   

Abstract

Among different classes of psychotropic drugs, hallucinogenic agents exert one of the most prominent effects on human and animal behaviors, markedly altering sensory, motor, affective, and cognitive responses. The growing clinical and preclinical interest in psychedelic, dissociative, and deliriant hallucinogens necessitates novel translational, sensitive, and high-throughput in vivo models and screens. Primate and rodent models have been traditionally used to study cellular mechanisms and neural circuits of hallucinogenic drugs' action. The utility of zebrafish ( Danio rerio ) in neuroscience research is rapidly growing due to their high physiological and genetic homology to humans, ease of genetic manipulation, robust behaviors, and cost effectiveness. Possessing a fully characterized genome, both adult and larval zebrafish are currently widely used for in vivo screening of various psychotropic compounds, including hallucinogens and related drugs. Recognizing the growing importance of hallucinogens in biological psychiatry, here we discuss hallucinogenic-induced phenotypes in zebrafish and evaluate their potential as efficient preclinical models of drug-induced states in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883191      PMCID: PMC3750682          DOI: 10.1021/cn400090q

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  178 in total

1.  Prenatal stress exposure alters postnatal behavioral expression under conditions of novelty challenge in rhesus monkey infants.

Authors:  M L Schneider
Journal:  Dev Psychobiol       Date:  1992-11       Impact factor: 3.038

2.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

3.  Scopolamine-induced learning impairment reversed by physostigmine in zebrafish.

Authors:  Yeon-Hwa Kim; Yunkyoung Lee; Dohee Kim; Min Whan Jung; Chang-Joong Lee
Journal:  Neurosci Res       Date:  2010-03-16       Impact factor: 3.304

4.  The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.

Authors:  M Lange; W Norton; M Coolen; M Chaminade; S Merker; F Proft; A Schmitt; P Vernier; K-P Lesch; L Bally-Cuif
Journal:  Mol Psychiatry       Date:  2012-04-17       Impact factor: 15.992

5.  Conditioned place preference behavior in zebrafish.

Authors:  Priya Mathur; Billy Lau; Su Guo
Journal:  Nat Protoc       Date:  2011-02-24       Impact factor: 13.491

6.  Behavioral performance altering effects of MK-801 in zebrafish (Danio rerio).

Authors:  Margarette Sison; Robert Gerlai
Journal:  Behav Brain Res       Date:  2011-02-17       Impact factor: 3.332

7.  Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.

Authors:  Gillinder Bedi; David Hyman; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

8.  Role of glutamate receptors in nucleus accumbens core and shell in spatial behaviour of rats.

Authors:  S Klein; M Hadamitzky; M Koch; K Schwabe
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 9.  Oxytocin, vasopressin and sociality.

Authors:  C Sue Carter; Angela J Grippo; Hossein Pournajafi-Nazarloo; Michael G Ruscio; Stephen W Porges
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

10.  Modulatory neurotransmitter systems and behavior: towards zebrafish models of neurodegenerative diseases.

Authors:  Pertti Panula; Ville Sallinen; Maria Sundvik; Juha Kolehmainen; Veera Torkko; Anu Tiittula; Maxim Moshnyakov; Piotr Podlasz
Journal:  Zebrafish       Date:  2006       Impact factor: 1.985

View more
  11 in total

Review 1.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

Review 2.  Zebrafish as an emerging model for studying complex brain disorders.

Authors:  Allan V Kalueff; Adam Michael Stewart; Robert Gerlai
Journal:  Trends Pharmacol Sci       Date:  2014-01-09       Impact factor: 14.819

Review 3.  Zebrafish models for translational neuroscience research: from tank to bedside.

Authors:  Adam Michael Stewart; Oliver Braubach; Jan Spitsbergen; Robert Gerlai; Allan V Kalueff
Journal:  Trends Neurosci       Date:  2014-04-09       Impact factor: 13.837

4.  Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology.

Authors:  Matthew N McCarroll; Leo Gendelev; Michael J Keiser; David Kokel
Journal:  ACS Chem Biol       Date:  2016-02-17       Impact factor: 5.100

5.  Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.

Authors:  Luisa Ponzoni; Daniela Braida; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2016-06-18       Impact factor: 4.530

6.  Gene alteration in zebrafish exposed to a mixture of substances of abuse.

Authors:  B Subedi; S Anderson; T L Croft; E C Rouchka; M Zhang; D R Hammond-Weinberger
Journal:  Environ Pollut       Date:  2021-02-24       Impact factor: 9.988

7.  Using visual lateralization to model learning and memory in zebrafish larvae.

Authors:  Madelene Åberg Andersson; Fredrik Ek; Roger Olsson
Journal:  Sci Rep       Date:  2015-03-02       Impact factor: 4.379

8.  Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.

Authors:  Margot A Cousin; Jon O Ebbert; Amanda R Wiinamaki; Mark D Urban; David P Argue; Stephen C Ekker; Eric W Klee
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

9.  Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery.

Authors:  Adam Michael Stewart; Robert Gerlai; Allan V Kalueff
Journal:  Front Behav Neurosci       Date:  2015-02-12       Impact factor: 3.558

10.  The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.

Authors:  Luisa Ponzoni; Daniela Braida; Gianpietro Bondiolotti; Mariaelvina Sala
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.